Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings in a new study. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.
